Why Raptor Pharmaceuticals Corp. Shares Clawed Higher

Raptor shares climbed after releasing interim data for its ongoing phase 2/3 trial for RP103, a treatment for Huntington's disease. Is it time to break out the pom-poms?

Feb 20, 2014 at 3:16PM

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Raptor Pharmaceuticals (NASDAQ:RPTP), a clinical-stage biopharmaceutical company focused on developing therapies to treat a number of serious diseases, including Huntington's disease and nonalcoholic steathohepatitis, jumped as much as 19% after announcing its clinical results from its phase 2/3 trial involving RP103 for Huntington's disease.

So what: To add some context to these results, this data is from the 18-month mark of a planned 36-month study. Thus far, 89 of 96 enrolled patients have reached the halfway point, speaking to the tolerability of Raptor's experimental treatment. The results, so far, demonstrate a "positive trend toward slower progression of Total Motor Score (TMS) in patients treated with RP103 vs. those patients on placebo, the primary endpoint of the study." Raptor notes TMS progression was 32% slower in patients treated with RP103 versus the placebo after 18 months, while the 66 patients not taking tetrabenazine (a treatment for chorea associated with Huntington's disease) demonstrated a "statistically significant slower progression in TMS vs. the placebo group."

Now what: It's a bit early to break out the pompons, but these results are certainly encouraging, and I fully understand why Raptor shares are clawing their way higher today. Safety and tolerability do not appear to be an issue with RP103. As a reminder for investors, Huntington's disease is an incredibly difficult disease to treat, so the failure rate of experimental therapies tends to be high. If Raptor can somehow succeed here where others have failed, it could certainly head much higher from its current valuation. Realistically, though, investors will have to wait for quite some time before the drug can hit the market, so I'd suggest you keep your expectations tempered in the meantime.

Raptor shareholders understand that revolutionary drugs can beget big gains. Under similar lines, our analysts have uncovered a revolutionary company that could be on the precipice of enormous gains!
Let's face it, every investor wants to get in on revolutionary ideas before they hit it big. Like buying PC-maker Dell in the late 1980's, before the consumer computing boom. Or purchasing stock in e-commerce pioneer Amazon.com in late 1990's, when they were nothing more than an upstart online bookstore. The problem is, most investors don't understand the key to investing in hyper-growth markets. The real trick is to find a small-cap "pure-play", and then watch as it grows in EXPLOSIVE lock-step with it's industry. Our expert team of equity analysts has identified 1 stock that's poised to produce rocket-ship returns with the next $14.4 TRILLION industry. Click here to get the full story in this eye-opening report for free.

Editor's Note: A previous version of this article suggested that the remainder of the RP103 clinical trial will be placebo-controlled. The article has been updated to provide more clarity.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any companies mentioned in this article. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers